GO:0003174 mitral valve development: Embryonic Process, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003174 (mitral valve development) describes the progression of the mitral valve over time, from its formation to the mature structure.
• The process depends on endocardial endothelial-to-mesenchymal transition (EndoMT), a critical source of valve interstitial cells.
• Disruption of mitral valve development leads to congenital and acquired valve diseases, including myxomatous degeneration and hypertrophic cardiomyopathy-related remodeling.
• Key genes include TGFB2, BMP2, NOTCH1, and TWIST1, which regulate EndoMT and valve remodeling.
• Research models range from animal pathology to tissue-engineered prostheses and computational simulations.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of candidate genes in mitral valve development.
Description
Mitral valve development (GO:0003174) is the biological process describing the progression of the mitral valve over time, from its formation to the mature structure. This process is essential for normal cardiac function, as the mitral valve controls blood flow between the left atrium and left ventricle. Defects in mitral valve development contribute to congenital heart anomalies and acquired valve diseases, making it a critical area of cardiovascular research. Understanding the molecular and cellular mechanisms of mitral valve development is fundamental for developing therapeutic strategies and tissue-engineered replacements. Recent advances in developmental biology have highlighted the role of endothelial-to-mesenchymal transition (EndoMT) in providing valve interstitial cells, a process regulated by multiple signaling pathways. This article synthesizes current knowledge on the genes, mechanisms, and research methods relevant to GO:0003174, providing a resource for researchers and clinicians.
mitral valve development At A Glance
| GO ID | GO:0003174 |
|---|---|
| GO term | mitral valve development |
| Ontology | biological_process |
| Synonym | None |
| Major function | Progression of the mitral valve from formation to mature structure |
| Related process | Endothelial-to-mesenchymal transition (EndoMT) |
| Key regulators | TGFB2, BMP2, NOTCH1, TWIST1 |
| Associated diseases | Myxomatous mitral valve disease, hypertrophic cardiomyopathy |
What Is GO:0003174?
GO:0003174 (mitral valve development) is defined as the progression of the mitral valve over time, from its formation to the mature structure. This encompasses the initial specification of valve precursor cells, endocardial cushion formation, remodeling into thin leaflets, and maturation of the stratified valve structure. The term is a biological process and has no synonyms in the QuickGO database.
Why Is mitral valve development Important in Cell Biology?
Mitral valve development is crucial because structural or functional defects in the valve lead to significant morbidity and mortality. Myxomatous mitral valve disease, characterized by leaflet thickening and prolapse, is the most common cause of mitral regurgitation in dogs and humans, and its pathology is rooted in developmental and remodeling processes. In hypertrophic cardiomyopathy, mitral valve remodeling contributes to left ventricular outflow tract obstruction, a major therapeutic target. Understanding the developmental origins of these diseases can inform regenerative medicine and surgical interventions, including transcatheter therapies and tissue-engineered prostheses.
• Mitral valve development is essential for normal cardiac function and blood flow.
• Defects in this process cause congenital mitral valve anomalies and acquired diseases.
• EndoMT is a key cellular mechanism providing valve interstitial cells.
• Myxomatous mitral valve disease involves developmental pathway dysregulation.
• Hypertrophic cardiomyopathy often includes mitral valve remodeling and obstruction.
• Transcatheter mitral valve interventions require understanding of valve anatomy and development.
• Tissue-engineered mitral valve prostheses aim to mimic native developmental structure.
• Animal models, especially dogs, provide insights into spontaneous mitral valve disease.
• Surgical simulators and high-fidelity models aid training and device development.
• Future technologies in cardiac surgery depend on developmental biology insights.
What Happens During mitral valve development?
Endocardial cushion formation
In simple terms: The heart's inner lining creates cushion-like structures that will become valve leaflets.
During early heart development, endocardial cells in the atrioventricular canal undergo endothelial-to-mesenchymal transition (EndoMT), delaminating and invading the underlying myocardium to form endocardial cushions. These cushions are the precursors of the mitral valve leaflets and are populated by mesenchymal cells derived from endocardium and epicardium. Signaling pathways such as TGF-beta and BMP are critical for this initial step.
Endothelial-to-mesenchymal transition (EndoMT)
In simple terms: Cells change from lining cells to migratory cells that build the valve.
EndoMT is a process where endothelial cells lose their cell-cell adhesions, acquire mesenchymal markers, and become migratory and invasive. In the developing mitral valve, EndoMT is regulated by TGFB2, BMP2, and NOTCH1 signaling. Disruption of EndoMT leads to hypocellular valves and developmental defects.
Valve leaflet remodeling and stratification
In simple terms: The cushions are sculpted into thin, layered leaflets.
After cushion formation, the mitral valve leaflets undergo remodeling, including apoptosis, extracellular matrix reorganization, and stratification into three layers: fibrosa, spongiosa, and atrialis. This process involves matrix metalloproteinases and their inhibitors, and defects can lead to myxomatous degeneration as seen in mitral valve disease.
Maturation and functional adaptation
In simple terms: The valve matures to withstand blood flow and close properly.
The mature mitral valve consists of two leaflets, chordae tendineae, and papillary muscles, all essential for proper closure during systole. Maturation involves continued ECM remodeling and cellular differentiation. In hypertrophic cardiomyopathy, abnormal mitral valve remodeling contributes to systolic anterior motion and outflow obstruction.
Key Genes Involved in GO:0003174 mitral valve development
The following genes are critical regulators of mitral valve development, as identified in the literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB2 | Regulates EndoMT and cushion formation | Mutations linked to valve defects |
| BMP2 | Promotes EndoMT and mesenchymal proliferation | Key mediator of valve development |
| NOTCH1 | Controls EndoMT and cell fate decisions | Associated with valve calcification |
| TWIST1 | Transcription factor driving EndoMT | Essential for mesenchymal phenotype |
| VEGFA | Angiogenic factor in valve remodeling | Influences valve vascularization |
| MMP2 | Extracellular matrix degradation | Implicated in myxomatous degeneration |
| MMP9 | ECM remodeling | Associated with valve pathology |
| TIMP1 | Inhibits MMPs | Regulates ECM turnover |
| COL1A1 | Collagen synthesis | Structural component of valve leaflets |
| COL3A1 | Collagen synthesis | Contributes to valve ECM |
| ELN | Elastin production | Important for valve elasticity |
| FBN1 | Fibrillin-1, ECM protein | Mutations cause Marfan syndrome with valve involvement |
| ACTA2 | Smooth muscle actin | Marker of activated interstitial cells |
| CDH5 | Endothelial adherens junction | Endothelial marker during EndoMT |
| SNAI1 | Transcriptional repressor of E-cadherin | Induces EndoMT |
| SNAI2 | Transcriptional repressor | Promotes mesenchymal phenotype |
| PRRX1 | Transcription factor in EndoMT | Regulates mesenchymal activation |
How Is mitral valve development Regulated?
Mitral valve development is regulated by a complex network of signaling pathways, including TGF-beta, BMP, NOTCH, and WNT. EndoMT is a key regulatory node, controlled by transcription factors such as TWIST1, SNAI1, and SNAI2. Extracellular matrix remodeling is regulated by matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), which influence leaflet stratification and maturation. Dysregulation of these pathways leads to valve disease, as seen in myxomatous degeneration and hypertrophic cardiomyopathy.
mitral valve development and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB2 | Myxomatous mitral valve disease | Knockout mouse, overexpression in valve interstitial cells |
| NOTCH1 | Valve calcification | Point mutation knock-in mouse |
| FBN1 | Marfan syndrome with mitral valve prolapse | Knock-in mouse model |
| MMP2 | ECM remodeling in valve disease | Knockout mouse |
| TWIST1 | EndoMT defects | Conditional knockout mouse |
Myxomatous mitral valve disease
Myxomatous mitral valve disease is characterized by leaflet thickening, prolapse, and regurgitation, and is the most common heart disease in dogs. The pathology involves accumulation of glycosaminoglycans and disruption of collagen architecture, reminiscent of developmental remodeling gone awry. Understanding the developmental pathways that are reactivated or dysregulated in this disease could lead to new therapies.
Hypertrophic cardiomyopathy (HCM)
In HCM, mitral valve remodeling contributes to left ventricular outflow tract obstruction and mitral regurgitation. Abnormal leaflet elongation and papillary muscle displacement are observed, and these changes may stem from developmental abnormalities. Surgical and transcatheter therapies targeting the mitral valve are important for HCM management.
Mitral valve stenosis
Congenital mitral valve stenosis is a rare developmental defect that can require transcatheter or surgical intervention. Understanding the developmental basis of stenosis can inform valve repair or replacement strategies.
From mitral valve development-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate EndoMT? | Knockout of gene X in endothelial cells |
| Does mutation Y cause valve thickening? | Point mutation knock-in mouse |
| Can overexpression of gene Z rescue valve defects? | Transgenic overexpression |
| Where is protein X localized during valve development? | Tagged knock-in (e.g., GFP) |
| What is the role of gene W in valve maturation? | Conditional knockout at specific stages |
| Can CRISPR screen identify novel valve regulators? | Pooled CRISPR library screening in valve cells |
How to Study the mitral valve development Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Single-cell RNA-seq | Gene expression at single-cell level | Identify valve cell subtypes |
| Lineage tracing | Cell origins and fate | Track EndoMT contribution |
| Immunohistochemistry | Protein localization | Validate gene expression in valve |
| CRISPR screen | Gene function in bulk | Discover novel regulators |
| Proteomics | Protein abundance and modifications | ECM composition analysis |
| Light-sheet microscopy | 3D morphology | Visualize valve development |
| qPCR | Gene expression levels | Validate candidate genes |
Lineage tracing and imaging
Lineage tracing using Cre-lox systems in mice allows visualization of EndoMT and valve cell contributions. Confocal and light-sheet microscopy provide three-dimensional views of developing valves.
Transcriptomics and single-cell RNA sequencing
Single-cell RNA sequencing can identify distinct cell populations in the developing mitral valve and reveal transcriptional programs driving EndoMT and remodeling.
Proteomics and ECM analysis
Mass spectrometry-based proteomics can quantify ECM components and signaling proteins in valve tissues, providing insights into remodeling.
Functional assays and CRISPR screens
CRISPR knockout screens in valve interstitial cells can identify genes required for proliferation, migration, and ECM production, accelerating target discovery.
How CRISPR Can Be Used to Study GO:0003174 mitral valve development
Knockout
CRISPR knockout of candidate genes in endothelial or valve interstitial cells can test their requirement for EndoMT and valve formation. For example, knocking out TGFB2 or BMP2 would impair cushion formation.
Point Mutation
Introducing specific point mutations (e.g., in NOTCH1 or FBN1) via CRISPR can model human valve diseases and reveal mechanistic insights.
Knock-in
Tagged knock-in (e.g., GFP or luciferase) allows real-time tracking of gene expression and protein localization during mitral valve development.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can test gain-of-function effects, such as whether increased TGFB2 signaling causes valve thickening.
How EDITGENE Supports mitral valve development Research
Researchers studying mitral valve development-related genes often need to determine whether a candidate gene is causally involved in EndoMT, valve remodeling, or disease progression. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for mitral valve development research.
Frequently Asked Questions About mitral valve development
What is GO:0003174?
GO:0003174 is the Gene Ontology term for mitral valve development, defined as the progression of the mitral valve over time, from its formation to the mature structure.
What genes are involved in mitral valve development?
Key genes include TGFB2, BMP2, NOTCH1, TWIST1, and SNAI1, which regulate EndoMT and valve remodeling.
What is the role of EndoMT in mitral valve development?
EndoMT provides mesenchymal cells that form the valve leaflets and is essential for cushion formation.
How is mitral valve development studied?
Researchers use lineage tracing, single-cell RNA-seq, CRISPR screens, and animal models to study this process.
What diseases are linked to mitral valve development?
Myxomatous mitral valve disease, hypertrophic cardiomyopathy, and congenital mitral stenosis are linked to developmental defects.
Can CRISPR be used to study mitral valve development?
Yes, CRISPR knockout, knock-in, and overexpression models enable functional testing of candidate genes.
What animal models are used for mitral valve research?
Mouse models are common, and dogs naturally develop myxomatous mitral valve disease.
What signaling pathways regulate mitral valve development?
TGF-beta, BMP, NOTCH, and WNT pathways are critical regulators.
What is the clinical relevance of mitral valve development?
Understanding development informs therapies for valve disease, including transcatheter interventions and tissue engineering.
How can I model mitral valve disease with CRISPR?
EDITGENE offers knockout, point mutation, knock-in, and overexpression services to model valve disease genes.
Conclusion
Mitral valve development (GO:0003174) is a complex biological process essential for cardiac function, involving EndoMT, cushion formation, and leaflet remodeling. Dysregulation of this process leads to prevalent diseases such as myxomatous mitral valve disease and hypertrophic cardiomyopathy. Continued research using advanced CRISPR models and multi-omics approaches will uncover new therapeutic targets and improve patient outcomes.
References
- 1. Fox PR. 2012. Pathology of myxomatous mitral valve disease in the dog.. J Vet Cardiol 14(1):103-26 PMID: 22386587
- 2. Bischoff J. 2019. Endothelial-to-Mesenchymal Transition.. Circ Res 124(8):1163-1165 PMID: 30973806
- 3. Moroni F et al.. 2023. Mitral valve remodeling in the development of obstructive hypertrophic cardiomyopathy.. Indian Heart J 75(4):308-310 PMID: 37348836
- 4. Kumar K et al.. 2024. Transcatheter Therapy for Mitral Valve Stenosis.. Cardiol Clin 42(3):447-454 PMID: 38910027
- 5. Sardari Nia P et al.. 2019. Development of a high-fidelity minimally invasive mitral valve surgery simulator.. J Thorac Cardiovasc Surg 157(4):1567-1574 PMID: 30385017
- 6. Kohorst K et al.. 2019. Future Technology.. Semin Cardiothorac Vasc Anesth 23(1):123-133 PMID: 29897014
- 7. Urena M et al.. 2023. Transcatheter mitral valve implantation for native valve disease.. EuroIntervention 19(9):720-738 PMID: 37994096
- 8. Moreira R et al.. 2014. TexMi: development of tissue-engineered textile-reinforced mitral valve prosthesis.. Tissue Eng Part C Methods 20(9):741-8 PMID: 24665896
